Mitochondrial targeted therapy with elamipretide (MTP-131) as an adjunct to tumor necrosis factor inhibition for traumatic optic neuropathy in the acute setting.

Tse BC, Dvoriantchikova G, Tao W, Gallo RA, Lee JY, Ivanov D, Tse DT, Pelaez D

Experimental eye research3 Aug 2020Cited by 11 (Europe PMC)

PMID32758490PMCIDPMC7554259DOI10.1016/j.exer.2020.108178PepBankPUB-32758490

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

1 result from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In mice with sonication-induced optic nerve trauma, subcutaneous MTP-131 alone increased retinal ganglion cell survival by 17% versus controls.
In plain wordsIn mice with optic nerve injury, injected MTP-131 alone raised retinal cell survival compared with controls.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseRetinal ganglion cell survival
Study
mousen: not reported in source
Sonication-induced traumatic optic neuropathy
Comparator
PBS-treated control eyes
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated · subcutaneousAs given in this study (mouse).
Measurements
RGC survival increase
17%
subcutaneous MTP-131 alone
Source sentences
Summary
while subcutaneous MTP-131 alone showed a 17% increase (p < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we investigated the effectiveness of elamipretide (MTP-131), a small mitochondrially-targeted tetrapeptide, in conjunction with etanercept, a tumor necrosis factor (TNF) inhibitor, as neuroprotective agents of retinal ganglion cells (RGCs) after optic nerve trauma with sonication-indu…
Report a problemFND-3275849003

Studies that did not test the peptide alone3

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

02AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In mice with sonication-induced optic nerve trauma, intravitreal MTP-131 plus subcutaneous etanercept and MTP-131 increased retinal ganglion cell survival by 21% versus PBS controls.
In plain wordsIn mice with optic nerve injury, a regimen of eye-injected MTP-131 plus injected etanercept and MTP-131 raised retinal cell survival compared with PBS.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseRetinal ganglion cell survival
Study
mousen: not reported in source
Sonication-induced traumatic optic neuropathy
Comparator
PBS-treated control eyes
Outcome group
Neuroprotection · Nervous system and cognition
Measurements
RGC survival increase
21%
intravitreal MTP-131 plus subcutaneous etanercept and MTP-131
Source sentences
Summary
Treatment with intravitreal MTP-131 and subcutaneous etanercept and MTP-131 showed a 21% increase (p < 0.01) in RGC survival rate compared to PBS-treated control eyes.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we investigated the effectiveness of elamipretide (MTP-131), a small mitochondrially-targeted tetrapeptide, in conjunction with etanercept, a tumor necrosis factor (TNF) inhibitor, as neuroprotective agents of retinal ganglion cells (RGCs) after optic nerve trauma with sonication-indu…
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3275849001
03AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In mice with sonication-induced optic nerve trauma, subcutaneous etanercept plus MTP-131 increased retinal ganglion cell survival by 11% versus controls.
In plain wordsIn mice with optic nerve injury, etanercept plus MTP-131 together raised retinal cell survival by 11% compared with controls.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseRetinal ganglion cell survival
Study
mousen: not reported in source
Sonication-induced traumatic optic neuropathy
Comparator
PBS-treated control eyes
Outcome group
Neuroprotection · Nervous system and cognition
Measurements
RGC survival increase
11%
subcutaneous etanercept and MTP-131
Source sentences
Summary
Subcutaneous etanercept and MTP-131 had an 11% increase (p < 0.05) in RGC survival compared to controls.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we investigated the effectiveness of elamipretide (MTP-131), a small mitochondrially-targeted tetrapeptide, in conjunction with etanercept, a tumor necrosis factor (TNF) inhibitor, as neuroprotective agents of retinal ganglion cells (RGCs) after optic nerve trauma with sonication-indu…
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3275849002
04AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In mice with sonication-induced optic nerve trauma, combined etanercept and MTP-131 showed no synergistic effect on retinal ganglion cell survival.
In plain wordsIn mice with optic nerve injury, giving etanercept and MTP-131 together did not add a synergistic benefit.
Peptide
Elamipretide (SS-31)
Outcome
No significant changeRetinal ganglion cell survival
Study
mousen: not reported in source
Sonication-induced traumatic optic neuropathy
Comparator
Single-drug groups
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
Surprisingly, we did not observe a synergistic effect between the two drugs in the group receiving both etanercept and MTP-131.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we investigated the effectiveness of elamipretide (MTP-131), a small mitochondrially-targeted tetrapeptide, in conjunction with etanercept, a tumor necrosis factor (TNF) inhibitor, as neuroprotective agents of retinal ganglion cells (RGCs) after optic nerve trauma with sonication-indu…
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3275849004

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 10:21 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.